anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Paragraph

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 118,471
Current window 34,591-34,620
Pages 3,950
Rows per page 30
Component: Paragraphclear collectionreset all
18 30 60

Component

34,591-34,620 of 118,471

filter-aware
202
The slide explicitly frames the narrative as a potential cover-up, contrasting patient statements with official physician office clarifications.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
205
The slide presents a qualitative case study (anecdotal evidence) regarding a potential adverse drug event.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
207
The slide uses a Q&A format to document a specific interaction between a doctor and a pharmaceutical sales representative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
211
The slide uses a table from a Lancet paper to argue that pitolisant's performance was inferior to modafinil, contradicting the company's narrative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
212
The slide uses a pie chart to highlight that 38% of study participants were in Russia, suggesting a lack of geographic diversity and potential data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
213
The slide uses a combination of narrative text and specific evidence (EMA table and ClinicalTrials.gov record) to prove the existence of a suppressed trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
224
The slide uses a 'red flag' argument to suggest data manipulation or p-hacking via sample size adjustment.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
235
The slide uses a strong, accusatory tone ('sycophancy', 'red flags') to frame the FDA's regulatory process as flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
239
The slide highlights the ambiguity in the definition of 'cataplexy' used in the study protocol, leading to potential data reliability issues.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
240
The slide uses ClinicalTrials.gov record history to demonstrate a 'red flag' in trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
242
The slide uses a CONSORT-style flow diagram to illustrate patient attrition in a clinical trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
244
The slide uses a comparative analysis of clinical trial data to challenge the validity of the HARMONY 3 results.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
245
The slide uses red text and boxes to emphasize the contradiction between the trial paper's claims and the EMA's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
254
The slide uses direct quotes from a KOL to undermine the market potential of Wakix.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
266
The slide highlights the physician's self-proclaimed influence and his personal relationship with sales reps, potentially exposing aggressive marketing tactics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
276
The slide contrasts the prescriber's relaxed attitude toward cardiac/hepatic monitoring with a specific, concerning anecdote about a patient experiencing uncontrollable anger.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
281
The slide presents a transcript of an interview with a physician, highlighting negative clinical experience.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
283
The slide uses a Q&A format to highlight a specific adverse event and the resulting loss of confidence in the drug's safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
284
The slide uses a Q&A format to document a specific adverse event case study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
301
The slide uses a specific academic paper to undermine the scientific premise of a drug's mechanism of action.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
304
The slide uses a direct quote from a scientific editorial to discredit a previously held hypothesis regarding pitolisant's mechanism of action.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
307
The slide uses a combination of narrative argument and direct excerpts from regulatory documents to highlight a discrepancy in drug efficacy claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
308
The slide uses a strong accusatory tone, alleging fraudulent claims and intent to mislead the FDA.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
319
The slide uses a Q&A format to validate the thesis of extreme concentration in prescribing behavior.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
321
The slide uses a Q&A format to highlight the 'quid pro quo' nature of the speaker programs.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
322
The slide presents a Q&A transcript excerpt highlighting a potential compliance issue regarding speaker programs and prescription volume.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
329
The slide uses a Q&A format to document unethical sales practices, specifically the verbal instruction to expand diagnoses to meet off-label sales goals.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
332
The slide uses a Q&A format to present whistleblower testimony regarding unethical sales practices.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
336
The slide uses a Q&A transcript format to highlight the 'weird' nature of the compensation process at Harmony.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
337
The slide uses a Q&A transcript format to highlight alleged unethical practices and lack of transparency in sales compensation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits